KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY.

Riccardo Tajè, Filippo Tommaso Gallina, Jonathan David Spicer

Ann Thorac Surg S0003-4975(26)00536-9

PMID42264017
PMCID-
DOI10.1016/j.athoracsur.2026.05.037
发表日期2026-06-09
AI 判定该论文不进入自动 KM 提取:This is a meta-analysis (specifically an individual patient data meta-analysis), which is excluded per the instructions. The record aggregates and analyzes data from prior trials rather than conducting a new phase III randomized controlled trial.
摘要

摘要

BACKGROUND: Neoadjuvant chemoimmunotherapy adoption in stage-II non-small cell lung cancer is shrouded by lack of clear survival advantages and stratification across randomized clinical trials. METHODS: An individual patient's data (IPD) meta-analysis was conducted comparing overall survival of stage-II patients (per AJCC TNM 8th version) receiving neoadjuvant chemoimmunotherapy in phase-3 randomized-controlled-trials with patients receiving upfront-surgery included in the pathological 8th and 9th-edition TNM-databases. IPD was extracted using the IPDfromKM method. Cox-regression-analyses estimated hazard-ratios (HR) and relative 95% confidence-intervals (95%CI). Meta-analysis and meta-regression comparing neoadjuvant chemoimmunotherapy and chemotherapy were also conducted. Relative-risk (RR) with 95%CI was derived. RESULTS: Overall-survival IPD was extracted from 275 stage-II patients receiving chemoimmunotherapy and from 6864 (8th-edition) and 7342 (9th-edition) patients receiving upfront-surgery in the pathological-TNM-database. Neoadjuvant chemoimmunotherapy improved survival compared to upfront-surgery in the 8th-edition TNM-database (HR=0.68, 95%CI 0.53-0.87, p=0.002) but yield similar survival compared to the 9th-edition (HR 0.82, 95%CI 0.64-1.1, p=0.10). Compared to chemotherapy, pathologic complete response (RR=6.19; 95%CI=3.37-10.27; p<0.001 and major pathologic response (RR=3.08; 95%CI 2.27-4.16; p<0.001) favored neoadjuvant chemoimmunotherapy. Similarly, chemoimmunotherapy improved event-free survival HR=0.66; 95%CI=0.52-0.82; p<0.001, and overall-survival (HR=0.68; 95%CI=0.50-0.92;p=0.01). Similar rates of cancelled surgery, open-surgery, pneumonectomy, conversion from minimally-invasive to open-surgery and positive margin were found. Percentage of stage-II patients did not modulate surgical-related adverse-events, 90-days mortality and adjuvant treatment receipt. CONCLUSIONS: Neoadjuvant chemoimmunotherapy has encouraging results in stage-II lung-cancer but stratification tools are warranted to select high-risk patients. Compared to chemotherapy, chemoimmunotherapy improves both long-term outcomes and pathological response with comparable surgical outcomes.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。